Can I Take Resveratrol with Addyi (Flibanserin)?

Why This Combination Raises a Red Flag

Flibanserin is one of only two FDA-approved drugs for HSDD in premenopausal women, and its labeling includes a boxed warning about CYP3A4 inhibitors [1]. Resveratrol, widely marketed for cardiovascular and longevity benefits, has demonstrated CYP3A4 inhibitory activity in preclinical models. That overlap puts the combination squarely in a gray zone: not proven dangerous in humans, but not proven safe either.

How Flibanserin Is Metabolized

Flibanserin undergoes extensive first-pass hepatic metabolism. CYP3A4 accounts for the largest share of oxidative biotransformation, with CYP2C19 contributing a secondary pathway [1]. The drug's oral bioavailability is approximately 33%, and its terminal half-life averages 11 hours. Any agent that slows CYP3A4 activity can raise peak plasma concentration (Cmax) and total exposure (AUC), amplifying dose-dependent adverse effects.

What Makes CYP3A4 Inhibition Dangerous Here

In a pharmacokinetic study cited in the Addyi label, co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased flibanserin AUC by 4.5-fold and Cmax by 1.8-fold [1]. Even the moderate inhibitor fluconazole raised AUC by approximately 7-fold in a separate analysis [1]. These increases translated directly into clinically significant drops in blood pressure and episodes of syncope, which prompted the FDA to contraindicate concomitant use with moderate or strong CYP3A4 inhibitors.

Resveratrol's Effect on CYP3A4

Resveratrol (trans-3,5,4'-trihydroxystilbene) is a stilbenoid polyphenol produced by several plants in response to stress. Supplement doses typically range from 100 mg to 1,500 mg daily, though some longevity-focused protocols exceed 2,000 mg.

In Vitro Evidence

Multiple in vitro studies have confirmed that resveratrol inhibits CYP3A4 catalytic activity. A 2010 study published in Drug Metabolism and Disposition found that resveratrol inhibited CYP3A4-mediated midazolam 1'-hydroxylation with a Ki of approximately 4.1 µM in human liver microsomes [2]. A separate analysis in Xenobiotica reported mechanism-based (time-dependent) inactivation of CYP3A4 by resveratrol, suggesting the inhibition could persist beyond the supplement's own elimination [3].

Human Pharmacokinetic Data

Translation from test tube to clinic is uncertain. Resveratrol has notoriously poor oral bioavailability. After a 500 mg oral dose, plasma concentrations of unconjugated resveratrol rarely exceed 1 to 2 µM, and most circulating resveratrol exists as sulfate and glucuronide conjugates with reduced CYP inhibitory potency [4]. A small crossover trial (N=12) found that 14 days of resveratrol 1,000 mg/day did not significantly alter midazolam pharmacokinetics, a standard CYP3A4 probe [5]. That result suggests the in vivo inhibitory effect at standard supplement doses may be clinically negligible for most substrates.

Why Caution Still Applies to Flibanserin

The midazolam probe study is reassuring but not conclusive for every CYP3A4 substrate. Flibanserin has a steeper dose-toxicity curve than midazolam: even a modest 30 to 50% AUC increase could push some patients past the threshold for symptomatic hypotension. The FDA label does not distinguish between "weak" and "moderate" CYP3A4 inhibitors with a safe cutoff; it simply contraindications moderate and strong inhibitors outright [1]. No regulatory body has formally classified resveratrol's in vivo CYP3A4 inhibitory strength, which means prescribers must rely on clinical judgment rather than a definitive category.

Pharmacodynamic Overlap: Estrogenic Activity

Beyond enzyme inhibition, resveratrol has a second theoretical interaction pathway. It acts as a phytoestrogen, binding estrogen receptor beta (ERβ) with modest affinity [6]. Flibanserin's mechanism of action (5-HT1A agonism / 5-HT2A antagonism) does not directly involve estrogen receptors, so a direct pharmacodynamic clash is unlikely.

Could Estrogenic Effects Alter HSDD Outcomes?

Some researchers have hypothesized that phytoestrogens could influence sexual desire through central or peripheral estrogen signaling. A 2014 review in Maturitas noted that phytoestrogen supplementation showed mixed results on female sexual function, with no consistent benefit on desire endpoints [7]. The clinical significance of resveratrol's weak ERβ binding in a woman already taking flibanserin is unknown, and no study has tested the pairing on HSDD endpoints.

What the FDA Label Says About Supplements

The Addyi prescribing information explicitly names pharmaceutical CYP3A4 inhibitors (ketoconazole, itraconazole, fluconazole, erythromycin, diltiazem, verapamil, and others) but does not mention resveratrol by name [1]. It does, however, include a general warning that "other inhibitors of CYP3A4" may increase flibanserin exposure.

The Grapefruit Parallel

The label warns against grapefruit juice consumption during Addyi treatment because furanocoumarin compounds in grapefruit are moderate intestinal CYP3A4 inhibitors [8]. This precedent matters. If a food-derived CYP3A4 inhibitor warrants a label warning, a concentrated polyphenol supplement with in vitro CYP3A4 inhibition deserves the same caution.

Supplement Dose Variability

Unlike prescription drugs, resveratrol supplements are not standardized under FDA drug manufacturing rules. A 2015 analysis in the Journal of Pharmaceutical and Biomedical Analysis found that actual resveratrol content in commercial products ranged from 15% to 115% of label claims [9]. Dose unpredictability increases the risk of unintentional higher-than-expected CYP3A4 inhibition.

If You Are Already Taking Both

Patients who discover they have been taking resveratrol alongside Addyi should not panic but should contact their prescriber promptly. The steps below reflect general clinical reasoning, not a substitute for individualized medical advice.

Step 1: Assess for Symptoms

Check whether you have experienced new or worsening dizziness, lightheadedness upon standing, or near-fainting episodes since starting the combination. These are the hallmark adverse effects of elevated flibanserin levels.

Step 2: Discuss with Your Prescriber

Your prescriber can evaluate whether the resveratrol dose you are taking poses a meaningful CYP3A4 inhibition risk. Doses below 250 mg/day with confirmed low-potency formulations carry less theoretical risk than 1,000+ mg/day products, though no formal threshold has been established for this pair.

Step 3: Consider a Washout Window

If you decide to continue both agents, some clinicians suggest a dose-separation strategy: taking resveratrol in the morning and Addyi at bedtime (its recommended administration time). Resveratrol's plasma half-life is roughly 1 to 3 hours for the unconjugated form [4], so a 12-hour gap minimizes overlap with peak CYP3A4 inhibition. This approach has not been validated in a controlled trial for this specific combination.

Step 4: Monitor Blood Pressure

Home blood pressure monitoring for the first 7 to 14 days of combined use provides an objective safety signal. A drop in systolic pressure of 20 mmHg or more compared to baseline, or any symptomatic orthostatic episode, should prompt discontinuation of one agent and medical evaluation.

Alcohol, Addyi, and Resveratrol: A Triple Risk

Addyi's REMS (Risk Evaluation and Mitigation Strategy) program exists largely because of the alcohol interaction [10]. In a clinical study, women who drank alcohol within 2 hours of taking flibanserin experienced clinically meaningful hypotension and, in some cases, syncope requiring medical intervention [1].

Why Red Wine Adds Another Layer

Patients who take resveratrol specifically because they associate it with the "French paradox" and red wine benefits may also be regular wine consumers. Red wine delivers both ethanol (a known Addyi risk factor) and small amounts of resveratrol. The triple combination of flibanserin plus supplemental resveratrol plus alcohol compounds both the pharmacokinetic and pharmacodynamic risk. If you take Addyi, avoid alcohol entirely, and recognize that resveratrol supplementation does not replicate the full cardiovascular effect profile attributed to moderate wine consumption.

Who Should Avoid This Combination Entirely

Certain patient populations face amplified risk from any CYP3A4 inhibition layered onto flibanserin therapy.

Patients on Other CYP3A4 Inhibitors

Women already taking a weak pharmaceutical CYP3A4 inhibitor (for example, oral contraceptives containing ethinyl estradiol, or certain SSRIs) sit closer to the inhibition ceiling. Adding resveratrol could push total CYP3A4 inhibitory burden from weak into functionally moderate territory. The Addyi label notes that multiple weak inhibitors used simultaneously can produce effects comparable to a single moderate inhibitor [1].

Hepatic Impairment

Flibanserin is contraindicated in patients with hepatic impairment of any degree because reduced hepatic CYP3A4 capacity already elevates drug exposure [1]. Resveratrol supplementation in this group would further compromise an already limited metabolic pathway.

Patients With Baseline Hypotension

Women with systolic blood pressure consistently below 100 mmHg, or those taking antihypertensives, face greater absolute risk from any additional blood pressure reduction caused by elevated flibanserin levels.

What Clinicians Should Document

For prescribers managing a patient who requests to use both agents, the Endocrine Society's general guidance on supplement-drug interactions recommends documenting three elements in the clinical note [11]:

1. The specific supplement product, dose, and frequency
2. The clinical rationale for continuing or discontinuing the supplement
3. A monitoring plan with defined stop criteria

This documentation protects both the patient and the prescriber if an adverse event occurs.

Bottom Line: A Cautious "Probably Not" Rather Than a Hard "No"

The available evidence does not support a definitive contraindication between standard-dose resveratrol and flibanserin. The in vivo CYP3A4 inhibition from typical resveratrol doses (250 to 500 mg/day) appears weak based on the midazolam probe study [5]. But flibanserin's steep safety margin, its FDA boxed warning, and the absence of any direct combination study mean that a prescriber-supervised approach is the only responsible path. Self-initiating resveratrol while on Addyi without medical input is not advisable.

Women who take Addyi at bedtime and want the antioxidant profile attributed to resveratrol should discuss lower-dose options (100 to 250 mg/day), morning-only dosing, and a 2-week blood pressure monitoring protocol with their prescriber before starting.